Novo Nordisk Stock Slumps After Ozempic Pill Fails in Alzheimer’s Trials

Novo Nordisk NOVO.B 3.80%increase; green up pointing triangle shares fell sharply after the Danish drugmaker said a pill with the key ingredient in Ozempic and Wegovy didn’t slow Alzheimer’s disease in two late-stage clinical trials.

The company said Monday that the ingredient, called semaglutide, wasn’t superior to a placebo in reducing the progression of Alzheimer’s disease in the studies.

Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8